Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF / VTE study

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

(2019) Stefan H Hohnloser et al.   EUROPEAN HEART JOURNAL

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

(2019) Pascal Vranckx et al.   LANCET

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

(2019) James D. Douketis et al.   JAMA Internal Medicine

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2018) Jan Steffel et al.   EUROPEAN HEART JOURNAL

OUP accepted manuscript

(2018)   EUROPEAN HEART JOURNAL

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

(2018) Ilaria Cavallari et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial

(2018) James Douketis et al.   THROMBOSIS AND HAEMOSTASIS

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design

(2018) Paolo Colonna et al.   CLINICAL CARDIOLOGY

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial

(2018) Jan Steffel et al.   EUROPACE

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

(2017) John U. Doherty et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPACE

Perioperative Management of DabigatranCLINICAL PERSPECTIVE

(2015) Sam Schulman et al.   CIRCULATION

The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis

(2015) Wengen Zhu et al.   CLINICAL CARDIOLOGY

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

(2014) D. Garcia et al.   BLOOD

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

(2014)   EUROPEAN HEART JOURNAL

Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry

(2014) J. Beyer-Westendorf et al.   EUROPEAN HEART JOURNAL

Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures

(2013) Todd H. Baron et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

(2012) Jeff S. Healey et al.   CIRCULATION

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

(2009) S. SCHULMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS